Transurethral electrovaporisation of the prostate (IPG14)
Fast, easy summary view of NICE guidance on 'lower urinary tract symptoms in men'
The National Institute for Health and Clinical Excellence (NICE) issued full guidance to the NHS in England, Wales, Scotland and Northern Ireland on transurethral electrovaporisation of the prostate in October 2003.
Further recommendations have been made as part of the clinical guideline on lower urinary tract symptoms published in May 2010, as follows:
- If offering surgery for managing voiding lower urinary tract symptoms (LUTS) presumed secondary to benign prostatic enlargement (BPE), offer monopolar or bipolar transurethral resection of the prostate (TURP), monopolar transurethral vaporisation of the prostate (TUVP) or holmium laser enucleation of the prostate (HoLEP).
Clinical and cost-effectiveness evidence was reviewed in the development of this guideline which has led to this more specific recommendation. More information is available from www.nice.org.uk/cg97. The IP guidance on transurethral electrovaporisation of the prostate remains current, and should be read in conjunction with the clinical guideline.
This procedure is used to treat benign prostatic obstruction (BPO.) BPO is a non-malignant enlargement of the prostate and is a common cause of lower urinary tract symptoms in men older than 40 years of age.
BPO can be managed either medically or surgically. The standard surgical treatment is transurethral resection of the prostate. However, relatively high morbidity for this procedure has led to the development of a range of minimally invasive techniques, some of which utilise thermal energy. Transurethral electrovaporisation of the prostate is one such technique which utilises high voltage electrical current to vaporise prostatic tissue and create a cavity in the prostate, so that symptoms caused by obstruction are reduced.
Transurethral electrovaporisation of the prostate, an electroablative technique, is performed with a specially designed modified rollerball electrode. Under general or spinal anaesthesia, electrical energy is applied for cutting and for coagulation. The electrode is rolled over the prostatic tissue to create an area of vaporisation of 3 to 4 mm and an underlying coagulative necrosis of 0.1 to 0.5mm. Vaporisation continues until an appropriate cavity is created.
M65.5 Endoscopic resection of prostate using vapotrode
Includes: Transurethral resection of prostate
The NHS Classifications Service of NHS Connecting for Health is the central definitive source for clinical coding guidance and determines the coding standards associated with the classifications (OPCS-4 and ICD-10) to be used across the NHS. The NHS Classifications Service and NICE work collaboratively to ensure the most appropriate classification codes are provided. www.connectingforhealth.co.uk/clinicalcoding
- IPG14 Transurethral electrovaporisation of the prostate: guidance (web format)
- IPG14 Transurethral electrovaporisation of the prostate: guidance
- IPG14 Transurethral electrovaporisation of the prostate: understanding NICE guidance
- IPG14 Transurethral electrovaporisation of the prostate: distribution list
- Interventional procedures consultation document - transurethral electrovaporisation of the prostate
- Overview of Transurethral electrovaporisation of the prostate (TEVAP)
This guidance has been incorporated into the following NICE Pathways, along with other related guidance and products.
Visit the NICE Pathway: lower urinary tract symptoms in men
This page was last updated: 25 October 2012
- Web format
- Full Guidance (PDF)
- IPG14 Electro-anweddu'r brostad trwy'r wrethra: deall canllawiau NICE
Information for the public
Implementation tools and resources
- None available
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.